I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
(Case C-442/11) (<span class="super">1</span>)
(The first subparagraph of Article 104(3) of the Rules of Procedure - Medicinal products for human use - Supplementary protection certificate - Regulation (EC) No 469/2009 - Articles 4 and 5 - Sole active ingredient for which such a certificate is granted - Scope of protection - Medicinal product containing more than one active ingredient, including the active ingredient which is the subject of a certificate)
2012/C 133/22
Language of the case: English
Applicant: Novartis AG
Defendant: Actavis UK Ltd
Reference for a preliminary ruling — High Court of Justice (Chancery Division) — Interpretation of Articles 4 and 5 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ 2009 L 152, p. 1) — Scope of the certificate — Protection only of medicinal products containing the protected active ingredient alone or protection also of medicinal products containing the protected active ingredient in combination with another active ingredient
Articles 4 and 5 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products must be interpreted as meaning that, where a ‘product’ consisting of an active ingredient was protected by a basic patent and the holder of that patent was able to rely on the protection conferred by that patent for that ‘product’ in order to oppose the marketing of a medicinal product containing that active ingredient in combination with one or more other active ingredients, a supplementary protection certificate granted for that ‘product’ enables its holder, after the basic patent has expired, to oppose the marketing by a third party of a medicinal product containing that product for a use of the ‘product’, as a medicinal product, which was authorised before that certificate expired.
(<span class="note">1</span>) OJ C 311, 22.10.2011.
* * *
Language of the case: English